AdvocateAuroraHealth™

REGEN-COV EUA Update
August 6, 2021

TYPE OF INFORMATION: Clinical Practice Change
INTENDED AUDIENCE: Physicians, Nurses, Pharmacists

Situation **S**	• The FDA recently updated the emergency use authorization (EUA) for the COVID monoclonal antibody combination casirivimab + imdevimab (REGEN-COV).
Background **B**	• The EUA for REGEN-COV was expanded to allow use for post-exposure prophylaxis against COVID-19 in individuals who are at least 12 years of age, weigh at least 40 kg, are at high risk for progression to severe COVID-19 disease, and are: o not fully vaccinated or who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications) **and** ▪ have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per CDC **or** ▪ who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes, prisons) • Criteria for designating a patient as high risk for progression to severe COVID-19 are the same as those used for treatment of COVID-19 with REGEN-COV.
Assessment **A**	• The dose and administration for prophylaxis is the same dose currently used for treatment of COVID-19: casirivimab/imdevimab 600mg/600mg over 20 minutes. - Patients must be observed for at least 60 minutes post-infusion for any symptoms of hypersensitivity reaction. • Epic orders for REGEN-COV will now ask prescribers to indicate whether REGEN-COV is being used for treatment or prophylaxis and then attest that the patient meets criteria. • The patient/family/caregiver fact sheet must be provided prior to the infusion. The link has been updated in Epic. • The same sites (ED and infusion clinics on a hospital campus) that are currently administering REGEN-COV for treatment may now also give REGEN-COV for prophylaxis if they have the capacity to do so. No additional sites will be added at this time. • The EUA also authorizes the use of REGEN-COV given as four subcutaneous injections. AAH will not be offering that option for either treatment or prophylaxis at this time. IV infusion is the preferred method per the EUA.
Recommendation **R**	• Effective immediately, AAH will offer REGEN-COV IV infusions for the indication of post-exposure prophylaxis against COVID-19 as defined above. • The dose for prophylaxis is casirivimab/imdevimab 600mg/600mg. • Epic orders have been updated to add prophylaxis as an indication for prescribers.
Questions? Please contact: Drug Policy Center at DPC@aah.org	

Date Issued: August 12, 2021
Post Through Date: September 6, 2021

Originating Department: Pharmacy, Advocate Aurora Health